Indian Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design (Interventional Trials, Observational Trials, Expanded Access Trials), By Indication, And Segment Forecasts, 2022 - 2030

Table of Contents

Chapter 1 Report Scope
1.1 Phase
1.2 Study Design
1.3 Indication
1.4 Estimates and Forecast Timeline
Chapter 2 Methodology
2.1 Research Methodology
2.1.1 Information Procurement
2.2 Information or Data Analysis
2.3 Market Formulation & Validation
2.4 Region Share Calculation
2.5 List of Secondary Sources
2.6 List of Primary Sources
2.7 List of Abbreviations
Chapter 3 Executive Summary
3.1 Market Snapshot
Chapter 4 Industry Outlook
4.1 Market Segmentation
4.2 Business Segment Trends
4.3 Market Variable Analysis
4.3.1 Market Driver Analysis
4.3.1.1 Globalization Of Clinical Trials
4.3.1.2 Adoption Of New Technology In Clinical Research
4.3.1.3 Growing Disease Variationnd Prevalence
4.3.1.4 Increasing Research And Development Promoting Outsourcing
4.3.2 Market Restraint Analysis
4.3.2.1 Pricing Pressure
4.3.2.2 Regulatory Issues.
4.4 Penetration & Growth Prospect Mapping
4.5 Business Environment Analysis tools
4.5.1 Swot Analysis, By Pest
4.5.2 Porter’s five forces analysis
4.5.3 Clinical Trial Registry.
4.5.4 The Objective Of The Registry
4.5.5 Future Prospects
4.5.6 Clinical Trial Registration Process Flow.
Chapter 5 Phase Estimates And Trend Analysis
5.1 Indian Clinical Trials Market: Phase Movement Analysis
5.2 Phase I
5.2.1 Phase I market estimates and forecast, 2018 - 2030 (USD Million)
5.3 Phase II
5.3.1 Phase II market estimates and forecast, 2018 - 2030 (USD Million)
5.4 Phase III
5.4.1 Phase III market estimates and forecast, 2018 - 2030 (USD Million)
5.5 Phase IV
5.5.1第四阶段市场估计和预测,2018年- 2030 (USD Million)
Chapter 6 Study Design Estimates And Trend Analysis
6.1 Indian Clinical Trials Market: Study Design Movement Analysis
6.2 Interventional trials
6.2.1 Interventional trials market estimates and forecast, 2018 - 2030 (USD Million)
6.3 Observational trials
6.3.1 Observational trials market estimates and forecast, 2018 - 2030 (USD Million)
6.4 Expanded access trials
6.4.1 Expanded access trials market estimates and forecast, 2018 - 2030 (USD Million)
Chapter 7 Indication Estimates And Trend Analysis
7.1 Indian Clinical Trials Market: Indication Movement Analysis
7.2自身免疫性/影响力ammation
7.2.1 Autoimmune/inflammation market estimates and forecast, 2018 - 2030 (USD Million)
7.2.2 Rheumatoid arthritis
7.2.3 rheumatoid arthritis market estimates and forecast, 2018 - 2030 (USD Million)
7.2.4 Multiple sclerosis
7.2.5 Multiple sclerosis market estimates and forecast, 2018 - 2030 (USD Million)
7.2.6 Osteoarthritis
7.2.7 Osteoarthritis market estimates and forecast, 2018 - 2030 (USD Million)
7.2.8 Irritable Bowel Syndrome (IBS)
7.2.9 Irritable Bowel Syndrome (IBS) market estimates and forecast, 2018 - 2030 (USD Million)
7.2.10 Others
7.2.11 others market estimates and forecast, 2018 - 2030 (USD Million)
7.3 Pain management
7.3.1 pain management market estimates and forecast, 2018 - 2030 (USD Million)
7.3.2 Chronic pain
7.3.3 Chronic pain market estimates and forecast, 2018 - 2030 (USD Million)
7.3.4 Acute pain
7.3.5 Acute pain market estimates and forecast, 2018 - 2030 (USD Million)
7.4 Oncology
7.4.1 Oncology market estimates and forecast, 2018 - 2030 (USD Million)
7.4.2 Blood cancer
7.4.3 Blood cancer market estimates and forecast, 2018 - 2030 (USD Million)
7.4.4 Solid tumors
7.4.5 Solid tumors market estimates and forecast, 2018 - 2030 (USD Million)
7.4.6 Other
7.4.7 Other market estimates and forecast, 2018 - 2030 (USD Million)
7.5 CNS Conditions
7.5.1 CNS conditions market estimates and forecast, 2018 - 2030 (USD Million)
7.5.2 Epilepsy
7.5.3 Epilepsy market estimates and forecast, 2018 - 2030 (USD Million)
7.5.4 Parkinson's Disease (PD)
7.5.5 Parkinson's disease market estimates and forecast, 2018 - 2030 (USD Million)
7.5.6 Huntington's Disease
7.5.7 Huntington's disease market estimates and forecast, 2018 - 2030 (USD Million)
7.5.8 Stroke
7.5.9 Stroke market estimates and forecast, 2018 - 2030 (USD Million)
7.5.10 Traumatic Brain Injury (TBI)
7.5.11 Traumatic Brain Injury (TBI) market estimates and forecast, 2018 - 2030 (USD Million)
7.5.12 Amyotrophic Lateral Sclerosis (ALS)
7.5.13 Amyotrophic Lateral Sclerosis (ALS) market estimates and forecast, 2018 - 2030 (USD Million)
7.5.14 Muscle regeneration
7.5.15 Muscle regeneration market estimates and forecast, 2018 - 2030 (USD million)
7.5.16 Others
7.5.17 Others market estimates and forecast, 2018 - 2030 (USD Million)
7.6 Diabetes
7.6.1 Diabetes market estimates and forecast, 2018 - 2030 (USD Million)
7.7 Obesity
7.7.1 Obesity market estimates and forecast, 2018 - 2030 (USD Million)
7.8 Cardiovascular
7.8.1 Cardiovascular market estimates and forecast, 2018 - 2030 (USD Million)
7.9 Others
7.9.1 Others market estimates and forecast, 2018 - 2030 (USD Million)
Chapter 8 Sponsors Design Estimates And Trend Analysis
8.1 Indian Clinical Trials Market: Sponsors Design Movement Analysis
8.2 Pharmaceutical & Biopharmaceutical Companies
8.2.1制药和生物制药公司market estimates and forecast, 2018 - 2030 (USD Million)
8.3 Medical Device Companies
8.3.1 Medical Device Companies market estimates and forecast, 2018 - 2030 (USD Million)
8.4 Others
8.4.1 Others market estimates and forecast, 2018 - 2030 (USD Million)
Chapter 9 Company Profiles
9.1 Strategic Framework
9.2 Company Profiles
9.2.1 IQVIA holdings Inc. (QUintilesIMS)
9.2.1.1 Company Overview
9.2.1.2 Financial Performance
9.2.1.3 Product Benchmarking
9.2.1.4 Strategic Initiatives
9.2.1.5 SWOT Analysis
9.2.2 Paraxel International Corporation
9.2.2.1 Company Overview
9.2.2.2 Financial Performance
9.2.2.3 Product Benchmarking
9.2.2.4 Strategic Initiatives
9.2.2.5 SWOT Analysis
9.2.3 Pharmaceutical Product Development, LLC
9.2.3.1 Company Overview
9.2.3.2 Financial Performance
9.2.3.3 Product Benchmarking
9.2.3.4 Strategic Initiatives
9.2.3.5 SWOT Analysis
9.2.4 Charles River Laboratory
9.2.4.1 Company Overview
9.2.4.2 Financial Performance
9.2.4.3 Product Benchmarking
9.2.4.4 Strategic Initiatives
9.2.4.5 SWOT Analysis
9.2.5 ICON plc
9.2.5.1 Company Overview
9.2.5.2 Financial Performance
9.2.5.3 Product Benchmarking
9.2.5.4 Strategic Initiatives
9.2.5.5 SWOT Analysis
9.2.6 PRA Health Sciences, INC.
9.2.6.1 Company Overview
9.2.6.2 Financial Performance
9.2.6.3 Product Benchmarking
9.2.6.4 Strategic Initiatives
9.2.6.5 SWOT Analysis
9.2.7 Chiltern International Ltd. (Covance Inc.)
9.2.7.1 Company Overview
9.2.7.2 Financial Performance
9.2.7.3 Product Benchmarking
9.2.7.4 Strategic Initiatives
9.2.7.5 SWOT Analysis
9.2.8 Syneos Health Inc. (inc research)
9.2.8.1 Company Overview
9.2.9.2 Financial Performance
9.2.8.3 Product Benchmarking
8.2.8.4 Strategic Initiatives.
9.2.8.5 SWOT Analysis
9.2.9 SGS SA
9.2.9.1 Company Overview
9.2.9.2 Financial Performance
9.2.9.3 Product Benchmarking
9.2.9.4 Strategic Initiatives
9.2.9.5 SWOT Analysis
9.2.10 Syngene International Limited
9.2.10.1公司概述
9.2.10.2 Financial Performance
9.2.10.3 Product Benchmarking
9.2.10.4 Strategic Initiatives
9.2.10.5 SWOT Analysis
9.2.11 Aurigene Discovery Technologies Limited
9.2.11.1 Company Overview
9.2.11.2 Financial Performance
9.2.11.3 Product Benchmarking
9.2.11.4 Strategic Initiatives
9.2.11.5 SWOT Analysis
9.2.12 Aragen Life Sciences
9.2.12.1 Company Overview
9.2.12.2 Financial Performance
9.2.12.3 Product Benchmarking
9.2.12.4 Strategic Initiatives
9.2.12.5 SWOT Analysis
9.2.13 Abiogenesis Clinpharm Pvt Ltd
9.2.13.1 Company Overview
9.2.13.2 Financial Performance
9.2.13.3 Product Benchmarking
9.2.13.4 Strategic Initiatives
9.2.13.5 SWOT Analysis
9.2.14 Accelsiors
9.2.14.1 Company Overview
9.2.14.2 Financial Performance
9.2.14.3 Product Benchmarking
9.2.14.4 Strategic Initiatives
9.2.14.5 SWOT Analysis
9.2.15 Accutest Global
9.2.15.1 Company Overview
9.2.15.2 Financial Performance
9.2.15.3 Product Benchmarking
9.2.15.4 Strategic Initiatives
9.2.15.5 SWOT Analysis
9.2.16 Clario
9.2.16.1 Company Overview
9.2.16.2 Financial Performance
9.2.16.3 Product Benchmarking
9.2.16.4战略举措
9.2.16.5 SWOT Analysis
9.2.17 Cliantha Research
9.2.17.1 Company Overview
9.2.17.2 Financial Performance
9.2.17.3 Product Benchmarking
9.2.17.4 Strategic Initiatives
9.2.17.5 SWOT Analysis
9.2.18 Cliniminds
9.2.18.1 Company Overview
9.2.18.2 Financial Performance
9.2.18.3 Product Benchmarking
9.2.18.4 Strategic Initiatives
9.2.18.5 SWOT Analysis
9.2.19 CliniRx
9.2.19.1 Company Overview
9.2.19.2 Financial Performance
9.2.19.3 Product Benchmarking
9.2.19.4 Strategic Initiatives
9.2.19.5 SWOT Analysis
9.2.20 JSS Medical Research
9.2.20.1 Company Overview
9.2.20.2 Financial Performance
9.2.20.3 Product Benchmarking
9.2.20.4 Strategic Initiatives
9.2.20.5 SWOT Analysis

List of Tables

Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 India Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
Table 4 India Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
Table 5 India Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)

List of Figures

Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value chain based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Indian clinical trials market summary
Fig. 9 Indian clinical trials market segmentation
Fig. 10 Market driver relevance analysis (Current & future impact)
Fig. 11 Market restraint relevance analysis (Current & future impact)
Fig. 12 Penetration & growth prospect mapping
Fig. 13 SWOT analysis, by factor (political & legal, economic and technological)
Fig. 14 Porter’s five forces analysis
Fig. 15 Phase wise clinical studies conducted in 2021
Fig. 16 Number of clinical trials conducted over the years in India
Fig. 17 Clinical trial registration process flow
Fig. 18 Indian clinical trials market phase outlook: Key takeaways
Fig. 19 Indian clinical trials market: Phase movement analysis
Fig. 20 Phase I market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 21 Phase II market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 22 Phase III market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 23 Phase IV market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 24 Indian clinical trials market study design outlook: Key takeaways
Fig. 25 Indian clinical trials market: study design movement analysis
Fig. 26 Interventional trials market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 27 Observational trials market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 28 Expanded access trials market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 29 Indian clinical trials market indication outlook: Key takeaways
Fig. 30 Indian clinical trials market: indication movement analysis
Fig. 31 Autoimmune/inflammation market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 32 Rheumatoid arthritis market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 33 Multiple sclerosis market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 34 Osteoarthritis market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 35 Irritable Bowel Syndrome (IBS) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 36 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 37 Pain management market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 38 Chronic pain market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 39 Acute pain market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 40 Oncology market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 41 Blood cancer market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 42 Solid tumors market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 43 Other market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 44 CNS Conditions market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 45 Epilepsy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 46 Parkinson's Disease market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 47 Huntington's Disease market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 48 Stroke market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 49 Traumatic Brain Injury (TBI) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 50 Amyotrophic Lateral Sclerosis (ALS) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 51 Muscle regeneration market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 52 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 53 Diabetes market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 54 Obesity market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 55 Cardiovascular market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 56 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 29 Indian clinical trials market end user outlook: Key takeaways
Fig. 30 Indian clinical trials market: end user movement analysis
Fig. 31 Pharmaceutical & Biopharmaceutical Companies market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 32 Medical Device Companies market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 33 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 34 Strategy framework